Related Experiment Video
Updated: Jun 2, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
An update on gene therapy in Parkinson's disease
Jennifer Witt1, William J Marks
1Department of Neurology, University of California, San Francisco, San Francisco, CA 94115, USA. jennifer.landes@ucsf.edu
Current Neurology and Neuroscience Reports
|April 12, 2011
Summary
Gene therapy for Parkinson's disease (PD) shows promise as a new treatment. Early clinical trials indicate encouraging safety and potential symptom relief, though more research is needed for efficacy confirmation.
Area of Science:
- Neuroscience
- Genetics
- Neurology
Background:
- Parkinson's disease (PD) treatments face limitations including motor complications, adverse effects, and lack of neuroprotection.
- Gene therapy offers a potential alternative by targeting specific pathways involved in PD.
Purpose of the Study:
- To review gene therapy strategies for PD, including dopamine delivery, GABA expression, and neurotrophic factor delivery.
- To summarize preclinical data and recent clinical trial findings for gene therapy agents in PD.
Main Methods:
- Review of preclinical rationale for different gene therapy strategies.
- Analysis of data from Phase 1 and Phase 2 clinical trials of four vector-gene agents for PD.
Main Results:
- Phase 1 trials demonstrated encouraging safety profiles for all four gene therapy agents.
- One Phase 2 trial indicated modest symptomatic efficacy, but further investigation is required.
Conclusions:
- Gene therapy for Parkinson's disease is advancing, with promising safety data from early trials.
- Definitive conclusions on the efficacy of gene therapy for PD cannot yet be drawn, necessitating further clinical evaluation.
More Related Videos
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
08:33Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
Published on: February 28, 2016
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...